newsfilter
← Latest News
Business Wire·

Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights

– Clinical observations from preliminary data at the lowest dose of MGTA-117 in a Phase 1/2 clinical trial indicate target binding, reduction of target cells in bone marrow, rapid drug clearance and a favorable tolerability profile – – IND-en